Saturday 17 October 2026
Export KPTI’s income statement to Excel — free account
Karyopharm Therapeutics Inc.
KPTI Healthcare Biotechnology
Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 11.9%, EPS grew 46.3%, free cash flow fell 33.3% and total debt rose 36.6%, each against the same quarter a year earlier.
0.39
0.04
+11.43%
Follow KPTI
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
2 | 3 | 4 | 4 | 3 | 4 | 3 | 3 | 2 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2,021.82 | 275.76 | 17.55 | 29.06 | 10.32 | 2.31 | 1.70 | 0.71 | 0.57 | 0.55 |
Altman Z-Score |
7.57 | (0.36) | (1.38) | (2.27) | (2.87) | (4.23) | (4.73) | (8.85) | (14.22) | (23.89) |
Altman Z″-Score (non-manufacturers) |
2.84 | (7.55) | (3.23) | (8.59) | (10.09) | (10.63) | (9.74) | (19.68) | (33.88) | (58.62) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | (1.30) | (2.09) | (1.47) | (3.93) | (0.70) | (8.05) |
P/Operating CF |
(18.10) | (82.26) | (11.05) | (30.09) | (36.42) | 18.99 | (9.95) | (5.54) | (3.19) | (6.80) |
P/B ratio |
2.23 | 3.52 | 2.91 | 23.87 | 22.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
2.23 | 3.52 | 2.91 | 23.87 | 22.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
1,298.06 | 186.97 | 10.11 | 25.35 | 9.10 | 2.00 | 1.02 | 0.58 | 1.11 | 1.67 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(2.75) | (4.19) | (1.93) | (5.43) | (6.14) | (3.93) | (1.08) | (0.92) | (1.26) | (3.23) |
EV/FCF |
(2.75) | (4.19) | (1.90) | (5.43) | (6.13) | (3.91) | (1.08) | (0.92) | (1.26) | (3.23) |
Quick Ratio |
7.86 | 2.97 | 7.00 | 5.85 | 4.40 | 3.49 | 4.95 | 3.15 | 1.51 | 0.98 |
Current Ratio |
7.99 | 3.00 | 7.13 | 6.01 | 4.59 | 3.74 | 5.31 | 3.37 | 1.70 | 1.12 |
Net Debt/EBITDA |
1.19 | 1.14 | 1.27 | 0.83 | 0.82 | 0.67 | 0.75 | 0.16 | (0.68) | (2.03) |
Debt/Assets |
0.00% | 0.00% | 30.09% | 37.80% | 38.28% | 56.21% | 48.29% | 71.09% | 113.96% | 209.28% |
Debt/Equity |
0.00 | 0.00 | 0.56 | 2.24 | 2.37 | (2.15) | (10.39) | (1.25) | (1.01) | (0.77) |
Asset Turnover |
0.00 | 0.01 | 0.12 | 0.13 | 0.36 | 0.68 | 0.47 | 0.49 | 0.72 | 1.07 |
Operating CF/Net income |
0.77 | 0.57 | 0.89 | 0.96 | 0.82 | 0.86 | 0.90 | 0.65 | 1.67 | 0.38 |
Capex/Depreciation |
(0.04) | (0.03) | (1.08) | (0.03) | (0.01) | (0.07) | (0.19) | 0.00 | (0.03) | 0.00 |
Interest Coverage |
(86.24) | (76.88) | (72.16) | (12.10) | (6.33) | (3.77) | (5.69) | (5.44) | (3.19) | (1.98) |
| (60.77%) | (88.43%) | (114.13%) | (171.36%) | (391.29%) | 852.05% | 343.18% | 187.23% | 47.43% | 81.86% | |
| (55.37%) | (71.52%) | (68.42%) | (62.75%) | (64.56%) | (40.13%) | (49.83%) | (47.81%) | (37.75%) | (143.71%) | |
ROIC |
(211.70%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(92.87%) | (127.53%) | (61.19%) | (84.84%) | (89.81%) | (60.97%) | (57.92%) | (86.70%) | (118.30%) | (1,751.91%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 70.17 | 43.50 | 39.14 | 109.42 | 67.39 | 77.32 | 65.42 |
Research and Development Expense of Revenue |
56,453.25% | 6,683.68% | 531.95% | 299.17% | 139.53% | 76.66% | 94.64% | 95.01% | 98.62% | 86.00% |
Selling, General and Administrative Expense of Revenue |
15,550.65% | 1,549.53% | 161.02% | 257.80% | 116.96% | 68.56% | 92.57% | 90.31% | 79.48% | 72.03% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
14,469.48% | 1,271.34% | 56.95% | 37.39% | 22.58% | 14.19% | 22.54% | 14.87% | 12.69% | 9.62% |
Graham Net Nets |
0.31 | 0.21 | 0.33 | 0.03 | 0.01 | (0.23) | (0.09) | (1.39) | (2.35) | (3.71) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 94.30 | 45.70 | 86.84 | 71.93 | 103.94 |
Earnings Yield |
(30.38%) | (28.21%) | (33.39%) | (16.84%) | (17.63%) | (25.80%) | (62.24%) | (138.61%) | (99.06%) | (243.54%) |
Free Cash Flow Yield |
(23.34%) | (16.20%) | (30.34%) | (16.08%) | (14.37%) | (22.20%) | (56.05%) | (90.16%) | (154.91%) | (93.82%) |
Revenue per Share |
0.06 | 0.52 | 8.01 | 9.90 | 22.49 | 41.82 | 28.76 | 19.17 | 17.88 | 13.36 |
Operating CF per Share |
(33.72) | (24.08) | (42.01) | (46.18) | (33.35) | (21.35) | (27.39) | (12.17) | (15.69) | (6.89) |
Capex per Share |
(0.03) | (0.02) | (0.62) | (0.05) | (0.03) | (0.04) | (0.02) | 0.00 | (0.02) | 0.00 |
Free Cash Flow per Share |
(33.75) | (24.10) | (42.64) | (46.23) | (33.38) | (21.39) | (27.41) | (12.17) | (15.71) | (6.89) |
Cash per Share |
51.76 | 47.91 | 86.66 | 63.66 | 52.38 | 46.83 | 51.10 | 25.22 | 13.38 | 5.83 |
Shareholders Equity per Share |
64.82 | 42.29 | 48.37 | 12.04 | 10.52 | (15.88) | (3.05) | (17.88) | (22.89) | (26.79) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
64.82 | 42.29 | 48.37 | 12.04 | 10.52 | (15.88) | (3.05) | (17.88) | (22.89) | (26.79) |
Free Cash Flow |
(84.46) | (73.78) | (161.48) | (191.03) | (160.38) | (107.33) | (149.67) | (92.72) | (127.63) | (75.37) |
Working Capital |
115.16 | 98.96 | 287.71 | 232.22 | 216.33 | 201.89 | 284.25 | 164.44 | 64.20 | 11.09 |
Capital Expenditures |
(0.07) | (0.06) | (2.36) | (0.21) | (0.14) | (0.21) | (0.12) | — | (0.14) | — |
Net Current Asset Value |
113.49 | 97.59 | 176.59 | 33.38 | 14.03 | (109.37) | (24.67) | (142.72) | (193.97) | (298.20) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.45 | 0.04 | 0.08 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.68 | 0.87 | 0.57 | 2.23 | 4.71 | 1.91 | 0.53 | (4.54) | 10.51 | 100.31 |
Cash ROIC |
(28.95%) | (26.72%) | (26.30%) | (45.02%) | (37.99%) | (32.83%) | (34.38%) | (40.88%) | (115.95%) | 3,295.54% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 3.94 | 10.42 | 11.86 | 4.51 | 3.94 | 5.03 | 5.13 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.91 | 1.00 | 1.12 | 2.38 | 1.68 | 1.46 | 1.31 |
Inventory Turnover |
— | — | — | 1.61 | 1.81 | 1.01 | 1.25 | 1.36 | 1.54 | 1.36 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 149.37 | 600.46 | 171.99 | 194.16 | 230.65 | 310.31 | 245.60 |
Days of Inventory on Hand |
— | — | — | 52.47 | 356.77 | 440.53 | 295.75 | 224.75 | 287.95 | 247.75 |
Average Receivables |
— | — | — | 10.37 | 10.37 | 17.69 | 34.79 | 37.02 | 28.86 | 28.47 |
Average Payables |
4.28 | 5.21 | 5.00 | 2.66 | 2.72 | 3.03 | 2.19 | 2.95 | 4.12 | 4.56 |
Average Inventory |
— | — | — | 1.50 | 1.50 | 3.38 | 4.17 | 3.63 | 3.89 | 4.39 |
Average Assets |
197.91 | 180.34 | 260.74 | 318.08 | 304.01 | 309.18 | 331.74 | 299.31 | 202.43 | 136.42 |
Average Common Equity |
180.30 | 145.85 | 156.32 | 116.47 | 50.16 | (14.56) | (48.16) | (76.43) | (161.11) | (239.47) |
Columns are period end dates